# OnCo record idea-tr1-public-dose-reduction-trials-of-approved-drugs (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tr1-public-dose-reduction-trials-of-approved-drugs/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tr1-public-dose-reduction-trials-of-approved-drugs" ;
  schema:name "Publicly funded dose-reduction trials of expensive approved drugs"@en ;
  schema:description "Some expensive approved cancer drugs probably work as well at lower doses, as reduced-dose abiraterone with food and extended-interval checkpoint inhibitors suggest. Companies will not test this, so payers should fund randomised non-inferiority trials prioritised by spend and pharmacology, and use the results in reimbursement."@en ;
  schema:url <https://onco.cc/ideas/idea-tr1-public-dose-reduction-trials-of-approved-drugs/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.anticancerfund.org/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/imatinib/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-incentive-misalignment/> .